基于活检来源活单细胞、表型生物标志物与机器学习的新型平台用于前列腺癌分级组1和2精准风险分层的临床概念验证
LPCP检测预测术后不良病理的受试者工作特征曲线下面积(AUC)大于0.80,并能区分前列腺癌分级组1、2与3(Gleason评分3+3、3+4与4+3),衍生生物标志物评分预测Gleason模式、分期及不良病理的AUC均大于0.80,结论称该检测以大于0.85的AUC将分级组1、2、3风险分层为预测有或无手术不良病理的亚组。
要点
- LPCP检测预测术后不良病理的AUC大于0.80,可区分前列腺癌分级组1、2与3。
- LPCP衍生生物标志物评分预测Gleason模式、分期及不良病理的AUC均大于0.80。
- MLDSA模型在70%活检细胞上训练、30%上测试,盲法预测与术后病理报告比较。
核心结论
- 基于MLDSA衍生的表型生物标志物评分,LPCP检测将前列腺癌分级组1、2、3(Gleason 3+3与7)风险分层为预测有或无手术不良病理的不同亚组,性能AUC大于0.85。
研究设计与样本
- 术中从已知癌区取新鲜前列腺样本,运送至中央实验室行LPCP检测,用机器视觉软件客观量化表型生物标志物。
- 通过机器学习衍生统计算法(MLDSA)对生物标志物客观排序以预测术后不良病理特征,在70%活检细胞上训练、剩余30%上测试。
主要发现
- LPCP检测预测根治性前列腺切除术后不良病理的AUC大于0.80,并能区分前列腺癌分级组1、2与3(Gleason评分3+3、3+4与4+3)。
- LPCP衍生生物标志物评分预测Gleason模式、分期及不良病理的AUC均大于0.80。
- 盲法预测与揭盲后根治性前列腺切除手术病理报告比较,确定敏感性与特异性。
关键数值与推荐
- 预测术后不良病理的AUC大于0.80;区分分级组1、2与3;衍生评分预测Gleason模式、分期及不良病理AUC大于0.80;风险分层性能AUC大于0.85。
- MLDSA在70%活检细胞上训练、30%上测试,覆盖所测试患者人群。
临床怎么用
- 该概念验证提示LPCP检测或可辅助前列腺癌分级组1和2患者术前风险分层,识别预测有或无术后不良病理的亚组。
- 检测使用根治性前列腺切除新鲜样本在中央实验室完成,尚处研究阶段,临床常规应用前需进一步验证。
局限性
- 为概念验证研究,样本来自根治性前列腺切除标本而非术前活检,与临床决策场景存在差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the ability of a novel live primary-cell phenotypic (LPCP) test to predict postsurgical adverse pathology (P-SAP) features and risk stratify patients based on SAP features in a blinded study utilizing radical prostatectomy (RP) surgical specimens. METHODS: Two hundred fifty-one men undergoing RP were enrolled in a prospective, multicenter (10), and proof-of-concept study in the United States. Fresh prostate samples were taken from known areas of cancer in the operating room immediately after RP. Samples were shipped and tested at a central laboratory. Utilizing the LPCP test, a suite of phenotypic biomarkers was analyzed and quantified using objective machine vision software. Biomarkers were objectively ranked via machine learning-derived statistical algorithms (MLDSA) to predict postsurgical adverse pathological features. Sensitivity and specificity were determined by comparing blinded predictions and unblinded RP surgical pathology reports, training MLDSAs on 70% of biopsy cells and testing MLDSAs on the remaining 30% of biopsy cells across the tested patient population. RESULTS: The LPCP test predicted adverse pathologies post-RP with area under the curve (AUC) via receiver operating characteristics analysis of greater than 0.80 and distinguished between Prostate Cancer Grade Groups 1, 2, and 3/Gleason Scores 3 + 3, 3 + 4, and 4 + 3. Further, LPCP derived-biomarker scores predicted Gleason pattern, stage, and adverse pathology with high precision-AUCs>0.80. CONCLUSION: Using MLDSA-derived phenotypic biomarker scores, the LPCP test successfully risk stratified Prostate Cancer Grade Groups 1, 2, and 3 (Gleason 3 + 3 and 7) into distinct subgroups predicted to have surgical adverse pathologies or not with high performance (>0.85 AUC).
引用
- Albala D, Manak MS, Varsanik JS, et al. Clinical Proof-of-concept of a Novel Platform Utilizing Biopsy-derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4). Urology. 2018. PMID: 30312670. doi:10.1016/j.urology.2018.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。